Can calcitonin gene-related peptide (CGRP) and pentraxin-3 (PTX-3) be useful in diagnosing acute migraine attack?

Vural, Sevilay; Albayrak, Levent

doi:10.1080/10799893.2022.2097264

Cited by 6 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding was confirmed by Pérez-Pereda and colleagues [ 42 ]. Interestingly, a positive correlation between serum CGRP levels and pain intensity was also reported [ 41 ]. It must, however, be noted that other studies did not report any changes in CGRP levels among EM and CM patients [ 42 , 43 , 44 , 45 , 46 ].…”

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 86%

“…Multiple studies conducted in patients assessed during the interictal phase report higher plasma/serum/saliva/CSF CGRP levels in EM and CM patients than in healthy controls (HC) [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 ]. Differently from EM and HC, Cernuda-Morollón and colleagues found elevated CGRP serum levels in CM women with and without acute medication overuse, suggesting a potential pathophysiological mechanism for CGRP in migraine chronification [ 35 ].…”

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 99%

“…PTX-3 serum levels increase during migraine attacks and are higher in the interictal phase in EM patients than in HC [ 41 , 162 , 163 ]. Since longer attacks are associated with lower serum levels of PTX-3, PTX-3 is not an indicator of pain intensity [ 41 ], while it may be correlated with the length of the disease [ 162 ], to suggest that inflammatory processes may change during migraine progression [ 162 ]. Increased interictal serum levels of PTX3 were also found in CM compared with HC [ 38 , 68 , 164 ].…”

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 99%

See 2 more Smart Citations

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings

Demartini

Francavilla

Zanaboni

et al. 2023

IJMS

View full text Add to dashboard Cite

In recent years, numerous efforts have been made to identify reliable biomarkers useful in migraine diagnosis and progression or associated with the response to a specific treatment. The purpose of this review is to summarize the alleged diagnostic and therapeutic migraine biomarkers found in biofluids and to discuss their role in the pathogenesis of the disease. We included the most informative data from clinical or preclinical studies, with a particular emphasis on calcitonin gene-related peptide (CGRP), cytokines, endocannabinoids, and other biomolecules, the majority of which are related to the inflammatory aspects and mechanisms of migraine, as well as other actors that play a role in the disease. The potential issues affecting biomarker analysis are also discussed, such as how to deal with bias and confounding data. CGRP and other biological factors associated with the trigeminovascular system may offer intriguing and novel precision medicine opportunities, although the biological stability of the samples used, as well as the effects of the confounding role of age, gender, diet, and metabolic factors should be considered.

show abstract

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 86%

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 99%

Section: The Potential Circulating Biomarkers Described In Migraine P...mentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings

Demartini

Francavilla

Zanaboni

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…For this point we need to explain that kits from USCN Life Sciences and Cloud Clone Corp., and from Peninsula Laboratories and BMA Biomedicals have been considered as only two brands since these companies have merged or have been acquired by the other at some point in their history. Moreover, and this last point serves as an example, there is a lack of information by part of the researchers regarding the kits used, because sometimes the brand cited offers more than one kit or two different brands over the history have been in charge of its production, and with the given information it cannot be inferred which one it was [ 27 , 34 ]. This could be the reason why across studies using kits from the same brand they obtained different concentrations.…”

Section: Discussionmentioning

confidence: 99%

Untangling the mess of CGRP levels as a migraine biomarker: an in-depth literature review and analysis of our experimental experience

Gárate,

Pascual,

Pascual-Mato

et al. 2024

J Headache Pain

View full text Add to dashboard Cite

Background Calcitonin gene-related peptide (CGRP) is the most promising candidate to become the first migraine biomarker. However, literature shows clashing results and suggests a methodological source for such discrepancies. We aimed to investigate some of these methodological factors to evaluate the actual role of CGRP as biomarker. Methods Previous to the experimental part, we performed a literature review of articles measuring CGRP in migraine patients. Using our 399 bio-bank sera samples, we performed a series of experiments to test the validity of different ELISA kits employed, time of sample processing, long-term storage, sampling in rest or after moderate exercise. Analysis of in-house data was performed to analyse average levels of the peptide and the effect of sex and age. Results Literature review shows the high variability in terms of study design, determination methods, results and conclusions obtained by studies including CGRP determinations in migraine patients. CGRP measurements depends on the method and specific kit employed, also on the isoform detected, showing completely different ranges of concentrations. Alpha-CGRP and beta-CGRP had median with IQR levels of 37.5 (28.2–54.4) and 4.6 (2.4–6.4)pg/mL, respectively. CGRP content is preserved in serum within the 24 first hours when samples are stored at 4°C after clotting and immediate centrifugation. Storages at -80°C of more than 6 months result in a decrease in CGRP levels. Moderate exercise prior to blood extraction does not modulate the concentration of the peptide. Age positively correlates with beta-CGRP content and men have higher alpha-CGRP levels than women. Conclusions We present valuable information for CGRP measurements in serum. ELISA kit suitability should be tested prior to the experiments. Alpha and beta-CGRP levels should be analysed separately as they can show different behaviours even within the same condition. Samples can be processed in a 24-h window if they have been kept in 4°C and should not be stored for more than 6 months at -80°C before assayed. Patients do not need to rest before the blood extraction unless they have performed a high-endurance exercise. For comparative studies, sex and age should be accounted for as these parameters can impact CGRP concentrations. Graphical Abstract

show abstract

“…It could be detected in the peripheral blood in pico levels. It is elevated after migraine attack and chronic migraine (2,3). Therefore, we can consider that intracranial structures are an important source of CGRP.…”

Section: Exogenous Cgrpmentioning

confidence: 99%

CGRP-induced headache and hemodynamic response for prediction of therapy based on CGRP antagonism

Zaletel

2023

Rad Hrvatske akademije znanosti i umjetnosti

View full text Add to dashboard Cite

Migraine is increasingly recognized as a disorder of the calcitonin gene-related peptide (CGRP) pathway. However, other factors are involved in migraine pathophysiology such as vasoactive intestinal peptide (VIP) and PACAP-38. Indeed, the CGRP-test can discriminate migraine from non-migraine and other non-CGRP induced migraine using CGRP-induced headache (CGRP-IH) and cerebral hemodynamic changes. Recent studies support the evidence of CGRP susceptible migraine prone to CGRP antagonism. Therefore, the CGRP-test may have an important role in therapeutic decisions regarding anti-CGRP monoclonal antibodies and gepants. This may improve the clinical effects of CGRP antagonism in migraine patients and increase therapeutic adherence. From the perspective of pain medicine may improve placebo response which can enhance favourable therapeutic outcomes.

show abstract

Can calcitonin gene-related peptide (CGRP) and pentraxin-3 (PTX-3) be useful in diagnosing acute migraine attack?

Cited by 6 publications

References 38 publications

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings

Untangling the mess of CGRP levels as a migraine biomarker: an in-depth literature review and analysis of our experimental experience

CGRP-induced headache and hemodynamic response for prediction of therapy based on CGRP antagonism

Contact Info

Product

Resources

About